Amgen的Raymond Deshaies在业界的reputation ranking如何？

[Tlexander]

Raymond Deshaies, Ph.D., is senior vice president, Global Research.

Prior to joining Amgen, Deshaies served as a professor at the California Institute of Technology (Caltech) and an executive officer in Caltech’s Division of Biology and Biological Engineering. He was also an investigator at the Howard Hughes Medical Institute.

In addition to his academic work, Deshaies co-founded Proteolix in 2003. In 2011, he co-founded Cleave Therapeutics.

Deshaies holds a bachelor's degree in biochemistry from Cornell University and a Ph.D. in biochemistry from the University of California, Berkeley. He is also a member of the American Academy of Arts and Sciences and National Academy of Sciences. In 2022, Fierce Pharma named Deshaies as one of the most influential people in biopharma.

Raymond Deshaies is a prominent biochemist and cell biologist known for his significant contributions to the field of protein degradation and ubiquitin-proteasome system (UPS) research. His main achievements include:

1. Discovery of the SCF Complex: Deshaies made a groundbreaking discovery in the late 1990s by identifying and characterizing the SCF (Skp1-Cul1-F-box protein) complex, which is a key component of the UPS. This complex plays a crucial role in tagging proteins for degradation by attaching them to ubiquitin molecules.

2. Elucidation of Ubiquitin Ligase Mechanisms: Deshaies contributed to the understanding of how the ubiquitin ligases recognize specific target proteins and facilitate their ubiquitination. He provided insights into the structure and function of various components of the ubiquitin ligase machinery, shedding light on the mechanisms underlying protein degradation.

3. Identification of Degron Sequences: Deshaies played a pivotal role in identifying specific sequences in target proteins, called degrons, which act as signals for recognition and subsequent degradation by the UPS. His work helped unravel the molecular basis of protein degradation and provided important insights into the regulation of protein stability.

4. Development of Chemical Genetic Approaches: Deshaies developed innovative chemical genetic approaches to investigate the UPS and protein degradation. He designed small molecules that could selectively inhibit or modulate specific components of the ubiquitin-proteasome system, enabling researchers to study the functions of individual proteins and pathways involved in protein degradation.

5. Advancement of Cancer Research: Deshaies' research has also had implications for cancer biology. Dysregulation of the UPS is implicated in various diseases, including cancer. His work on the ubiquitin-proteasome system has provided insights into the mechanisms underlying cancer progression and has opened up new avenues for developing targeted therapies.

Raymond Deshaies' contributions have significantly advanced our understanding of protein degradation and the ubiquitin-proteasome system, with wide-ranging implications for various areas of biological research, including cell biology, biochemistry, and cancer biology.